Snapshot from Aug 24, 2026 at 07:00 UTC. For live data and tracking: View Live
Events / Regulatory / Diagnos receives Saudi FDA approval for CARA
Regulatory regulatory approval

Diagnos receives Saudi FDA approval for CARA

Analysis based on 7 articles · First reported Aug 13, 2026 · Last updated Aug 13, 2026

Sentiment
20
Attention
2
Articles
7
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard
Market Impact

The approval opens a new market for Diagnosis's CARA system, potentially increasing future revenue streams. The stock may see a modest positive reaction given the expanded commercial opportunity, though the immediate financial impact is limited.

Healthcare Medical Devices Artificial Intelligence
Event Summary

On August 13, 2026, Diagnosis Inc., a Canadian company specializing in AI-based early detection of eye diseases, announced that it received Medical Device Marketing Authorization for its CARA System from the Saudi Arabia — Saudi Food and Drug Authority (SFDA). The CARA System includes detection algorithms for Diabetic Retinopathy (DR) and Age-related Macular Degeneration (AMD). This approval allows Diagnosis to market CARA in Saudi Arabia, where the adult population is 25 million with a 23% diabetes prevalence, representing an addressable market of over 5 million adults. The company plans to use local distributors, notably Kanhoor Medical, to penetrate the Saudi market. This approval follows a recent Canada — Health Canada approval in July 2026, expanding Diagnosis's commercial opportunities beyond North America. Executives including COO Yves-Stephane Couture, CEO André Larente, and Chairman Philippe Couillard highlighted the milestone's significance for the company and Quebec's innovation ecosystem.

Entities Involved
govactor
Saudi Arabia — Saudi Food and Drug Authority
The SFDA granted the marketing authorization, acting as the regulatory gatekeeper. Its decision enables Diagnosis's entry into the Saudi market.
Importance 80.0 Sentiment 0.0
cnt
Saudi Arabia
Saudi Arabia is the target market, with a large diabetic population and significant screening needs. The approval allows CARA to be used there, potentially improving healthcare outcomes.
Importance 70.0 Sentiment 0.0
priv
Kanhoor Medical
Kanhoor Medical is the local distributor in Saudi Arabia, expected to facilitate market penetration. Its role is supportive but not central to the approval.
Importance 50.0 Sentiment 0.0
govactor
Canada — Health Canada
Canada — Health Canada's prior approval in July 2026 is referenced as a recent milestone, but it is not directly part of this event.
Importance 40.0 Sentiment 0.0
per
André Larente
André Larente, CEO of Diagnosis, commented on the approval, emphasizing its importance for expanding sales beyond North America. His leadership is relevant to the company's strategy.
Importance 40.0 Sentiment 0.0
ngo
International Diabetes Federation
The IDF provided statistics on diabetes prevalence in Saudi Arabia, highlighting the market size. It is not directly affected by the event.
Importance 30.0 Sentiment 0.0
per
Yves-Stephane Couture
Yves-Stephane Couture, COO, called the authorization a milestone in commercialization efforts. His role is operational.
Importance 30.0 Sentiment 0.0
per
Philippe Couillard
Philippe Couillard, Chairman, highlighted the achievement for Quebec's innovation ecosystem. His role is largely ceremonial in this context.
Importance 20.0 Sentiment 0.0
exch
TSX Venture Exchange
TSX Venture Exchange is the listing venue for Diagnosis. It is not directly impacted by the approval.
Importance 10.0 Sentiment 0.0
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.